Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced additional results of the phase 2 clinical trial with obeticholic acid (OCA), a potent farnesoid X receptor agonist …
Analyst Alan Carr of Needham weighed in on Intercept Pharmaceuticals (NASDAQ:ICPT) and Cempra Inc (NASDAQ:CEMP) today. Intercept Pharmaceuticals Carr maintains a Buy rating on …
Wedbush analyst Liana Moussatos weighed in with her views on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after the company released its second-quarter results, posting $0.445 million in licensing revenue, compared to consensus …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Today was supposed to be a great day for Intercept Pharmaceuticals stock as the company announced forward movement in …
Wedbush’s healthcare analyst Liana Moussatos weighed in with her views on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after the company’s two competitors announced phase 2 results …